M
Matthew M. Cooney
Researcher at Case Western Reserve University
Publications - 80
Citations - 5824
Matthew M. Cooney is an academic researcher from Case Western Reserve University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 24, co-authored 77 publications receiving 4853 citations. Previous affiliations of Matthew M. Cooney include University of Kentucky & University Hospitals of Cleveland.
Papers
More filters
Journal ArticleDOI
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher Sweeney,Yu-Hui Chen,Michael A. Carducci,Glenn Liu,David F. Jarrard,Mario A. Eisenberger,Yu-Ning Wong,Noah M. Hahn,Manish Kohli,Matthew M. Cooney,Robert Dreicer,Nicholas J. Vogelzang,Joel Picus,Daniel H. Shevrin,Maha Hussain,Jorge A. Garcia,Robert S. DiPaola +16 more
TL;DR: Six cycles of docetaxel at the beginning of ADT for metastatic prostate cancer resulted in significantly longer overall survival than that with ADT alone.
Journal ArticleDOI
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos Kyriakopoulos,Yu-Hui Chen,Michael A. Carducci,Glenn Liu,David F. Jarrard,Noah M. Hahn,Daniel H. Shevrin,Robert Dreicer,Maha Hussain,Mario A. Eisenberger,Manish Kohli,Elizabeth R. Plimack,Nicholas J. Vogelzang,Joel Picus,Matthew M. Cooney,Jorge A. Garcia,Robert S. DiPaola,Christopher Sweeney +17 more
TL;DR: The clinical benefit from chemohormonal therapy in prolonging OS was confirmed for patients with high-volume disease; however, for patientsWith low- volume disease, no OS benefit was discerned.
Journal ArticleDOI
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
Robert G. Maki,David R. D'Adamo,Mary L. Keohan,Michael Saulle,Scott M. Schuetze,Samir D. Undevia,Michael B. Livingston,Matthew M. Cooney,Martee L. Hensley,Monica M. Mita,Chris H. Takimoto,Andrew S. Kraft,Anthony D. Elias,Bruce Brockstein,Nathalie E. Blachere,Mark A. Edgar,Lawrence H. Schwartz,Li-Xuan Qin,Cristina R. Antonescu,Gary K. Schwartz +19 more
TL;DR: As a single agent, sorafenib has activity against angiosarcoma and minimal activity against other sarcomas, and statistical modeling in this limited patient cohort indicated sorafinib toxicity was correlated inversely to patient height.
Journal ArticleDOI
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
William D. Tap,William D. Tap,Robin L. Jones,Robin L. Jones,Brian A. Van Tine,Bartosz Chmielowski,Anthony D. Elias,Douglas Adkins,Mark Agulnik,Matthew M. Cooney,Michael B. Livingston,Gregory K. Pennock,Meera Hameed,Gaurav D. Shah,Amy Qin,Ashwin Shahir,Damien M. Cronier,Robert Ilaria,Ilaria Conti,Jan Cosaert,Gary K. Schwartz +20 more
TL;DR: An open-label phase 1b and randomised phase 2 study of doxorubicin plus olaratumab treatment in patients with unresectable or metastatic soft-tissue sarcoma at 16 clinical sites in the USA, finding progression-free survival in phase 2 was 6.6 months and the efficacy was assessed.
Journal Article
A Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer
Afshin Dowlati,Kelly Robertson,Matthew M. Cooney,William P. Petros,Michael Stratford,John A. Jesberger,Niusha Rafie,Beth Overmoyer,Vinit Makkar,Bruce S. Stambler,Anne L. Taylor,John Waas,Jonathan S. Lewin,Keith R. McCrae,Scot C. Remick +14 more
TL;DR: The toxicity profile of CA4P on a single-dose i.v. schedule is consistent with a drug that is "vascularly active" and devoid of traditional "cytotoxic" side effects.